Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems t
Bayer has shored up its near-term pipeline by acquiring European rights to acoramidis from BridgeBio and Eidos Therapeutics, putting some big pharma muscle behind the ther
Our round-up of recent biotech financings is headed by a massive $1.25 billion round for genetic medicines specialist BridgeBio Pharma, with smaller rounds for Tr1X, Coman
BridgeBio Pharma has raised $250 million from the sale of nine million shares that is earmarked for the commercial launch of its acoramidis drug for transthyretin amyloido
Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
